NeoStem to Present at LifeTech Capital Miami Medical Investors Conference

Nov 10 2010

NeoStem, Inc. (NYSE Amex: NBS), an international biopharmaceutical company with operations in the U.S. and China, announced today that Chief Executive Officer Robin Smith, M.D., MBA, will present on some of the latest developments at the Company at the LifeTech Capital Miami Medical Investors Conference to be held at the JW Marriott Marquis Miami on November 12, 2010. In addition, Dr. Smith has been selected to appear on a science and industry panel with the leading medical researchers from the University of Miami Miller School of Medicine.

Dr. Smith will participate in the Innovations in Science & Industry Panel #1 from 8:30 am to 9:00 am in the Main Ballroom and then will present from 9:30 am to 9:50 am in Presentation Room #1.

The LifeTech Capital Miami Medical Investors Conference brings together promising biotechnology companies and medical and scientific key opinion leaders with institutional and accredited investors from across the country. More information can be found at http://www.LifeTechCapital.com/conference.

"I am excited to present on NeoStem's latest developments at the first annual LifeTech Capital Miami Medical Investors Conference. I look forward to providing details on our recent research and development efforts and partnerships, especially those looking at potential applications of our VSEL™ Technology," said Dr. Robin Smith.

About NeoStem, Inc.

NeoStem, Inc. is engaged in the development of stem cell-based therapies, pursuit of anti-aging initiatives and building of a network of adult stem cell collection centers in the U.S. and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The Company is also the licensee of various stem cell technologies, including a worldwide exclusive license to VSEL™ Technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit: http://www.neostem.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include the future of VSEL™ Technology and adult stem cells as a viable treatment option, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.